Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biodesix Inc
(NQ:
BDSX
)
1.610
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biodesix Inc
< Previous
1
2
3
4
Next >
Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services
July 06, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier
June 27, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting
June 01, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Participate in William Blair’s 43rd Annual Growth Stock Conference
May 31, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing
May 25, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix, Inc. Chief Financial Officer Robin Harper Cowie Appointed to Colorado BioScience Association's Board of Directors
May 24, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference
May 18, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces First Quarter 2023 Results and Highlights
May 11, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Report First Quarter 2023 Financial Results on May 11, 2023
April 27, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights
March 06, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Participate at Cowen’s 43rd Annual Healthcare Conference
February 28, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
February 21, 2023
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test
December 19, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors
December 16, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine
December 12, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
November 21, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock
November 17, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Proposed Public Offering of Common Stock
November 16, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million
November 16, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 10, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Third Quarter 2022 Results and Highlights
November 03, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022
October 20, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions
October 17, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs
October 12, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Preliminary Revenue for Third Quarter 2022
October 11, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Participate in Two Upcoming Investor Conferences in September
September 06, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Named a Top 100 Healthcare Technology Company of 2022
August 09, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix Announces Second Quarter 2022 Results and Highlights
August 04, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 03, 2022
From
Biodesix, Inc.
Via
Business Wire
Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors
July 20, 2022
From
Biodesix, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.